Aprea Therapeutics Inc. (APRE)
2.10
-0.10 (-4.55%)
At close: Mar 28, 2025, 3:59 PM
2.23
6.29%
After-hours: Mar 28, 2025, 05:11 PM EDT
Company Description
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel cancer therapeutics that target DNA damage response pathways.
Its lead product candidate is ATRN-119, an oral ATR inhibitor that is in phase 1/2a clinical trial to treat patients with advanced solid tumors.
The company's products pipeline also includes ATRN-Backup, an ATR inhibitor; ATRN-W1051 to treat anti-tumor activity; and ATRN-DDRi. Aprea Therapeutics, Inc. is based in Boston, Massachusetts.
Aprea Therapeutics Inc.
| Country | United States |
| IPO Date | Oct 3, 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 7 |
| CEO | Dr. Oren Gilad Ph.D. |
Contact Details
Address: 535 Boylston St. Boston, Massachusetts United States | |
| Website | https://atrinpharma.com |
Stock Details
| Ticker Symbol | APRE |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001781983 |
| CUSIP Number | 03836J102 |
| ISIN Number | US03836J2015 |
| Employer ID | 00-0000000 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Oren Gilad Ph.D. | Co-Founder, Chief Executive Officer, President & Director |
| Andrea Epstein | Controller |
| Brian Wiley | Senior Vice President of Corporate Development & Strategy |
| Dr. Lars B. Abrahmsen Ph.D. | Senior Vice President & Chief Scientific Officer |
| Dr. Michel Afargan Ph.D. | Head of Pharmacology Development |
| Ze'ev Weiss B.Sc., C.P.A. | Chief Business Advisor |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 25, 2025 | 10-K | Annual Report |
| Mar 25, 2025 | 8-K | Current Report |
| Feb 13, 2025 | SCHEDULE 13G/A | [Amend] Filing |
| Feb 10, 2025 | SCHEDULE 13G/A | [Amend] Filing |
| Feb 10, 2025 | SCHEDULE 13G/A | [Amend] Filing |
| Feb 05, 2025 | 8-K | Current Report |
| Jan 13, 2025 | 8-K | Current Report |
| Nov 14, 2024 | SCHEDULE 13G | Filing |
| Nov 08, 2024 | 8-K | Current Report |
| Nov 08, 2024 | 424B5 | Filing |